Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

10 evidence topics · 11 sources

Summary: anticipated place in therapy

Inaxaplin is investigational, and no labeled indication exists. The pivotal AMPLITUDE trial enrolls participants aged 10 to 65 years with two APOL1 variants (G1/G1, G2/G2, or G1/G2), a urine protein to creatinine ratio (UPCR) of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2, and excludes people with diabetes mellitus, a solid organ or bone marrow transplant, or another known cause of kidney disease. Inaxaplin is given as 45 mg once daily on top of standard of care. Vertex states that a positive AMPLITUDE interim analysis could form the basis for potential U.S. accelerated approval, and Vertex investor relations stated that AMPLITUDE could unlock a population of about 150,000 people in the U.S. and Europe. Vertex estimates approximately 100,000 further people with AMKD and comorbidities such as type 2 diabetes. The phase 2 AMPLIFIED study dosed 41 participants with modest proteinuria (cohort 1, n=23) or with type 2 diabetes (cohort 2, n=18), populations Vertex describes as not being studied in AMPLITUDE, and Fierce Biotech reported that an FDA label covering both cohorts would add about 100,000 people to the target population.

Use would depend on APOL1 genotyping. A Vertex-sponsored test describes a genetic test for two APOL1 risk variants as required for a definitive diagnosis of AMKD; trial eligibility used a Vertex-designated investigational assay, and the Vertex-sponsored Labcorp test states that it has not been cleared or approved by the FDA. A Delphi consensus panel agreed that nephrologists should counsel patients about APOL1 high-risk genotypes, order the test, and return results, and that if a treatment becomes available all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with counseling. The KDIGO Controversies Conference report states that when treatments become available, “patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount”. In a U.S. real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5 at a mean age of 45.6 years, 35.7% had at least one administration or fill of a RAAS inhibitor, and 10.5% of an SGLT2 inhibitor.

Populations evaluated beyond the pivotal trial: AMPLIFIED